Oxford Covid-19 vaccine shows 70% efficacy in phase 2/3 trials
Oxford University’s AstraZeneca vaccine candidate, AZD1222, against coronavirus disease (Covid-19) has shown 70% efficacy on average, according to the newly published data of phase 2/3 clinical trials held in the United Kingdom and Brazil, the company announced on Monday.
In effect, the results mean that of all the people who get vaccinated, about 70% will not be infected by the disease.
Also, experts had tried two different dosing regimens, of which one showed a better profile—close to 90% efficacy.
“Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing Covid-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine,” said AstraZeneca in a statement issued on Monday.
“One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%,” the statement read.
Also Watch l Covid vaccine: How much will you have to pay? SII CEO reveals at #HTLS2020
The data analysed by an independent Data Safety Monitoring Board (DSMB) determined that the analysis met its primary endpoint showing protection from Covid-19 occurring two weeks or more after receiving two doses of the vaccine.
“These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply,” said Andrew Pollard, chief investigator, Oxford vaccine trial at oxford, in a statement.
Additionally, no serious safety events related to the vaccine have been confirmed, and the vaccine was well-tolerated across both dosing regimens.
Since the results are based on an interim data analysis, the company has said it will be conducting additional analysis based on further data that gets generated over time, to refine efficacy reading and establish the duration of protection.
AstraZeneca is now preparing regulatory submissions of the data to authorities around the world that have a framework in place for conditional or early approval.
“The Company will seek an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal,” the company statement read.
Enter your email to get our daily newsletter in your inbox
- ‘Chalo get moving with me’: Tahira Kashyap tells fans that ‘it’s never too late’ to get your health routine back and we are already brushing aside mid-week blues and workout excuses with these exercises at home, courtesy her encouraging fitness video | Watch
- In a recent study, scientists have said that it’s re-assuring that the kind of Covid-19 spread seen in US nursing homes and other places hasn’t been noted in schools with prevention measures but extracurricular activities like sports, have triggered coronavirus spread in some places
- Tiger Shroff took to Instagram and shared an awe-generating video of himself nailing a flying kick in his gym while holding the Indian Flag in his hand.
- Fitness enthusiast Malaika Arora makes sure that every week she shares a new Yoga asana with her followers and inspire them to exercise. This week the actor talked about the benefits and steps of the Bridge Pose.
- A new study done by the researchers of Georgetown Lombardi Comprehensive Cancer and MedStar Washington Hospital Center shows that men who suffer from breast cancer might be more susceptible to cardiovascular diseases.